Guilin Sanjin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 2.68

Guilin Sanjin Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) is 2.68 on January 14, 2025, a -8.21% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Guilin Sanjin Pharmaceutical Co., Ltd. 52-week high Price to Book Ratio (P/B) is 3.35 on October 08, 2024, which is 25.08% above the current Price to Book Ratio (P/B).
Guilin Sanjin Pharmaceutical Co., Ltd. 52-week low Price to Book Ratio (P/B) is 2.43 on February 02, 2024, which is -9.10% below the current Price to Book Ratio (P/B).
Guilin Sanjin Pharmaceutical Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 2.85.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 002275.SZ

Guilin Sanjin Pharmaceutical Co., Ltd.

CEO	Mr. Xun Zou
IPO Date	July 10, 2009
Location	China
Headquarters	No.1, Gold Star(Jinxing) Road
Employees	2,615
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. The company was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

Key trends

Past 5 years